Your browser doesn't support javascript.
A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
Janssen, Maike; Schäkel, Ulrike; Djuka Fokou, Carine; Krisam, Johannes; Stermann, Jacek; Kriegsmann, Katharina; Haberbosch, Isabella; Novotny, Jan Philipp; Weber, Stefan; Vehreschild, Maria; Bornhäuser, Martin; Bullinger, Lars; Schmitt, Michael; Liebregts, Tobias; Dreger, Peter; Lorenz, Hanns-Martin; Plaszczyca, Anna; Bartenschlager, Ralf; Müller, Barbara; Kräusslich, Hans-Georg; Halama, Niels; Jäger, Dirk; Schlenk, Richard F; Leo, Albrecht; Meuer, Stefan; Weigand, Markus A; Motsch, Johann; Merle, Uta; Denkinger, Claudia M; Müller-Tidow, Carsten.
  • Janssen M; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany. maike.janssen@med.uni-heidelberg.de.
  • Schäkel U; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Djuka Fokou C; NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany.
  • Krisam J; Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany.
  • Stermann J; Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany.
  • Kriegsmann K; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Haberbosch I; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Novotny JP; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Weber S; Division of Tropical Medicine, Department of Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany.
  • Vehreschild M; Division of Tropical Medicine, Department of Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany.
  • Bornhäuser M; Division of Infectious Diseases, University Hospital Frankfurt, Frankfurt, Germany.
  • Bullinger L; University Hospital Dresden, Dresden, Germany.
  • Schmitt M; Charité University Medicine, Berlin, Germany.
  • Liebregts T; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Dreger P; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Lorenz HM; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Plaszczyca A; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Bartenschlager R; Department of Infectious Diseases, Molecular Virology, Heidelberg University Hospital, Heidelberg, Germany.
  • Müller B; Department of Infectious Diseases, Molecular Virology, Heidelberg University Hospital, Heidelberg, Germany.
  • Kräusslich HG; Department of Infectious Diseases, Virology, Heidelberg University Hospital, Heidelberg, Germany.
  • Halama N; Department of Infectious Diseases, Virology, Heidelberg University Hospital, Heidelberg, Germany.
  • Jäger D; Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Schlenk RF; Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Leo A; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
  • Meuer S; NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany.
  • Weigand MA; Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Motsch J; Institute for Clinical Transfusion Medicine and Cell Therapy Heidelberg, Heidelberg, Germany.
  • Merle U; Institute for Clinical Transfusion Medicine and Cell Therapy Heidelberg, Heidelberg, Germany.
  • Denkinger CM; Department of Anaesthesiology, Heidelberg University Hospital, Heidelberg, Germany.
  • Müller-Tidow C; Department of Anaesthesiology, Heidelberg University Hospital, Heidelberg, Germany.
Trials ; 21(1): 828, 2020 Oct 06.
Article in English | MEDLINE | ID: covidwho-1388814
Semantic information from SemMedBD (by NLM)
1. American College of Cardiology/American Heart Association Lesion Complexity Score C PROCESS_OF Patients
Subject
American College of Cardiology/American Heart Association Lesion Complexity Score C
Predicate
PROCESS_OF
Object
Patients
2. Severe disorder PROCESS_OF Patients
Subject
Severe disorder
Predicate
PROCESS_OF
Object
Patients
3. Severe Acute Respiratory Syndrome PROCESS_OF Patients
Subject
Severe Acute Respiratory Syndrome
Predicate
PROCESS_OF
Object
Patients
4. Discharg PROCESS_OF C0030705
Subject
Discharg
Predicate
PROCESS_OF
Object
C0030705
5. Disease PROCESS_OF Patients
Subject
Disease
Predicate
PROCESS_OF
Object
Patients
6. Antibodies PART_OF 2019 novel coronavirus
Subject
Antibodies
Predicate
PART_OF
Object
2019 novel coronavirus
7. Antibodies TREATS Severe Acute Respiratory Syndrome
Subject
Antibodies
Predicate
TREATS
Object
Severe Acute Respiratory Syndrome
8. Antibodies TREATS American College of Cardiology/American Heart Association Lesion Complexity Score C
Subject
Antibodies
Predicate
TREATS
Object
American College of Cardiology/American Heart Association Lesion Complexity Score C
9. Antibodies TREATS Patients
Subject
Antibodies
Predicate
TREATS
Object
Patients
10. AKR1A1 wt Allele LOCATION_OF Crossing Ove
Subject
AKR1A1 wt Allele
Predicate
LOCATION_OF
Object
Crossing Ove
11. American College of Cardiology/American Heart Association Lesion Complexity Score C PROCESS_OF Patients
Subject
American College of Cardiology/American Heart Association Lesion Complexity Score C
Predicate
PROCESS_OF
Object
Patients
12. Severe disorder PROCESS_OF Patients
Subject
Severe disorder
Predicate
PROCESS_OF
Object
Patients
13. Severe Acute Respiratory Syndrome PROCESS_OF Patients
Subject
Severe Acute Respiratory Syndrome
Predicate
PROCESS_OF
Object
Patients
14. Discharge, body substance PROCESS_OF Patients
Subject
Discharge, body substance
Predicate
PROCESS_OF
Object
Patients
15. Disease PROCESS_OF Patients
Subject
Disease
Predicate
PROCESS_OF
Object
Patients
16. Antibodies PART_OF 2019 novel coronavirus
Subject
Antibodies
Predicate
PART_OF
Object
2019 novel coronavirus
17. Antibodies TREATS Severe Acute Respiratory Syndrome
Subject
Antibodies
Predicate
TREATS
Object
Severe Acute Respiratory Syndrome
18. Antibodies TREATS American College of Cardiology/American Heart Association Lesion Complexity Score C
Subject
Antibodies
Predicate
TREATS
Object
American College of Cardiology/American Heart Association Lesion Complexity Score C
19. Antibodies TREATS Patients
Subject
Antibodies
Predicate
TREATS
Object
Patients
20. AKR1A1 wt Allele LOCATION_OF Crossing Over, Genetic
Subject
AKR1A1 wt Allele
Predicate
LOCATION_OF
Object
Crossing Over, Genetic
ABSTRACT

OBJECTIVES:

Primary objectives • To assess the time from randomisation until an improvement within 84 days defined as two points on a seven point ordinal scale or live discharge from the hospital in high-risk patients (group 1 to group 4) with SARS-CoV-2 infection requiring hospital admission by infusion of plasma from subjects after convalescence of SARS-CoV-2 infection or standard of care. Secondary objectives • To assess overall survival, and the overall survival rate at 28 56 and 84 days. • To assess SARS-CoV-2 viral clearance and load as well as antibody titres. • To assess the percentage of patients that required mechanical ventilation. • To assess time from randomisation until discharge. TRIAL

DESIGN:

Randomised, open-label, multicenter phase II trial, designed to assess the clinical outcome of SARS-CoV-2 disease in high-risk patients (group 1 to group 4) following treatment with anti-SARS-CoV-2 convalescent plasma or standard of care.

PARTICIPANTS:

High-risk patients >18 years of age hospitalized with SARS-CoV-2 infection in 10-15 university medical centres will be included. High-risk is defined as SARS-CoV-2 positive infection with Oxygen saturation at ≤ 94% at ambient air with additional risk features as categorised in 4 groups • Group 1, pre-existing or concurrent hematological malignancy and/or active cancer therapy (incl. chemotherapy, radiotherapy, surgery) within the last 24 months or less. • Group 2, chronic immunosuppression not meeting the criteria of group 1. • Group 3, age ≥ 50 - 75 years meeting neither the criteria of group 1 nor group 2 and at least one of these criteria Lymphopenia < 0.8 x G/l and/or D-dimer > 1µg/mL. • Group 4, age ≥ 75 years meeting neither the criteria of group 1 nor group 2. Observation time for all patients is expected to be at least 3 months after entry into the study. Patients receive convalescent plasma for two days (day 1 and day 2) or standard of care. For patients in the standard arm, cross over is allowed from day 10 in case of not improving or worsening clinical condition. Nose/throat swabs for determination of viral load are collected at day 0 and day 1 (before first CP administration) and subsequently at day 2, 3, 5, 7, 10, 14, 28 or until discharge. Serum for SARS-Cov-2 diagnostic is collected at baseline and subsequently at day 3, 7, 14 and once during the follow-up period (between day 35 and day 84). There is a regular follow-up of 3 months. All discharged patients are followed by regular phone calls. All visits, time points and study assessments are summarized in the Trial Schedule (see full protocol Table 1). All participating trial sites will be supplied with study specific visit worksheets that list all assessments and procedures to be completed at each visit. All findings including clinical and laboratory data are documented by the investigator or an authorized member of the study team in the patient's medical record and in the electronic case report forms (eCRFs). INTERVENTION AND COMPARATOR This trial will analyze the effects of convalescent plasma from recovered subjects with SARS-CoV-2 antibodies in high-risk patients with SARS-CoV-2 infection. Patients at high risk for a poor outcome due to underlying disease, age or condition as listed above are eligible for enrollment. In addition, eligible patients have a confirmed SARS-CoV-2 infection and O2 saturation ≤ 94% while breathing ambient air. Patients are randomised to receive (experimental arm) or not receive (standard arm) convalescent plasma in two bags (238 - 337 ml plasma each) from different donors (day 1, day 2). A cross over from the standard arm into the experimental arm is possible after day 10 in case of not improving or worsening clinical condition. MAIN

OUTCOMES:

Primary endpoints The main purpose of the study is to assess the time from randomisation until an improvement within 84 days defined as two points on a seven-point ordinal scale or live discharge from the hospital in high-risk patients (group 1 to group 4) with SARS-CoV-2 infection requiring hospital admission by infusion of plasma from subjects after convalescence of a SARS-CoV-2 infection or standard of care. Secondary endpoints • Overall survival, defined as the time from randomisation until death from any cause 28-day, 56-day and 84-day overall survival rates. • SARS-CoV-2 viral clearance and load as well as antibody titres. • Requirement mechanical ventilation at any time during hospital stay (yes/no). • Time until discharge from randomisation. • Viral load, changes in antibody titers and cytokine profiles are analysed in an exploratory manner using paired non-parametric tests (before - after treatment). RANDOMISATION Upon confirmation of eligibility (patients must meet all inclusion criteria and must not meet exclusion criteria described in section 5.3 and 5.4 of the full protocol), the clinical site must contact a centralized internet randomization system ( https//randomizer.at/ ). Patients are randomized using block randomisation to one of the two arms, experimental arm or standard arm, in a 11 ratio considering a stratification according to the 4 risk groups (see Participants). BLINDING (MASKING) The study is open-label, no blinding will be performed. NUMBERS TO BE RANDOMISED (SAMPLE SIZE) A total number of 174 patients is required for the entire trial, n=87 per group. TRIAL STATUS Protocol version 1.2 dated 09/07/2020. A recruitment period of approximately 9 months and an overall study duration of approximately 12 months is anticipated. Recruitment of patients starts in the third quarter of 2020. The study duration of an individual patient is planned to be 3 months. After finishing all study-relevant procedures, therapy, and follow-up period, the patient is followed in terms of routine care and treated if necessary. Total trial duration 18 months Duration of the clinical phase 12 months First patient first visit (FPFV) 3rd Quarter 2020 Last patient first visit (LPFV) 2nd Quarter 2021 Last patient last visit (LPLV) 3rd Quarter 2021 Trial Report completed 4th Quarter 2021 TRIAL REGISTRATION EudraCT Number 2020-001632-10, https//www.clinicaltrialsregister.eu/ctr-search/trial/2020-001632-10/DE , registered on 04/04/2020. FULL PROTOCOL The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2). The eCRF is attached (Additional file 3).
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Plasma / Pneumonia, Viral / Coronavirus Infections / Pandemics / Betacoronavirus / Antibodies, Viral Type of study: Controlled clinical trial / Diagnostic study / Etiology study / Clinical Practice Guide / Randomized controlled trials / Risk factors Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Trials Journal subject: Medicine / Therapeutics Year: 2020 Document Type: Article Affiliation country: S13063-020-04735-Y

Full text: Available Collection: International databases Database: MEDLINE Main subject: Plasma / Pneumonia, Viral / Coronavirus Infections / Pandemics / Betacoronavirus / Antibodies, Viral Type of study: Controlled clinical trial / Diagnostic study / Etiology study / Clinical Practice Guide / Randomized controlled trials / Risk factors Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Trials Journal subject: Medicine / Therapeutics Year: 2020 Document Type: Article Affiliation country: S13063-020-04735-Y